MENU

Why These Dow Stocks Fell in May

Close-up of Electronic Stock TickerUS – Until the big swoon on Friday, the stock market had been crushing just about every bullish investor’s wildest dreams for positive returns, with nearly a couple dozen new record highs so far during the year. For those who believed that May would finally mark the end of the long four-year bull market, the month’s overall performance was disappointing, as the Dow Jones Industrials (DJINDICES: ^DJI) gained almost 2% during May.

But just because the overall average rose doesn’t mean that every company shared its good fortune. Fully a third of the Dow’s 30 components lost ground during the month. Let’s take a look at the four that lost more than 5% on the month to see what we can identify from their performance.

Verizon (NYSE: VZ), down 10.1%, and AT&T (NYSE: T), down 6.6%
Addressing both of the Dow’s telecom giants makes sense given the common traits they share. Both of them have high dividends and rely on their extensive wireless networks for large portions of their revenue, and both have made huge investments in building up those networks over time. As a result, both were vulnerable when one analyst argued that GoogleFiber could challenge the entire way that the two telecoms offer triple-play video, voice, and data to their customers. In addition, the drop in the bond market over the past week also isolated the two high-dividend payers, as higher interest rates make the value of the discounted stream of future revenue the two telecom giants earn less valuable in terms of present value. Neither AT&T nor Verizon need to worry about competition too much right now, but further bond-market weakness could push shares downward even from these lower levels.

Pfizer (NYSE: PFE), down 5.6%
Like the two telecoms, Pfizer suffered its worst losses in the last part of the month. The same argument regarding dividend stocks applies just as well to Pfizer as to AT&T and Verizon. But in addition, Pfizer shareholders face an interesting decision in the near future about whether to hang onto their shares or exchange them for shares of Pfizer’s 80%-owned animal-health unit Zoetis. Offering roughly a 7% discount to make the exchange, Pfizer shareholders will feel pressure to accept the Zoetis offer, but the impact it will have to both companies’ shares going forward is uncertain. Some investors might well simply prefer to sell their shares now rather than facing that dilemma, especially given that Zoetis shares saw similar declines. In the long run, though, Pfizer’s success depends on the success or failure of its drug pipeline, so keep an eye on news related to new drug prospects rather than getting bogged down in the Zoetis deal.

Coca-Cola (NYSE: KO), down 5.5%
In addition to the interest rate issue, Coke suffered some company-specific bad news last week. A worker strike in Venezuela has eaten into Coke’s revenue from the South American country, and although that won’t make a substantial hit to the company’s overall sales, the stock’s response shows just how sensitive it is to even the hint of bad news. Given a relatively high valuation despite its growth challenges, Coke needs to resolve its issues promptly to get back moving in the right direction.

What’s next for these stocks?
If the Dow follows through on Friday’s 200-point decline with further losses, these stocks look like reasonable prospects to keep suffering. Only if we see a reversal in sentiment should investors expect short-term bounces from the stocks. From a long-term perspective, however, these stocks all have favorable traits, making any share-price decline right now a potential buying opportunity.

To keep up-to-date with what’s happening in the US and Singapore markets, click here now for your FREE subscription to Take Stock Singapore, The Motley Fool’s free investing newsletter. Written by David Kuo, Take Stock Singapore tells you exactly what’s happening in today’s markets, and shows how you can GROW your wealth in the years ahead.  

Like us on Facebook   to keep up-to-date with our latest news and articles. The Motley Fool’s purpose is to help the world invest, better.

The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. This article was written by Dan Caplinger, and first published on fool.com

All information is provided by The Motley Fool Singapore Pte Ltd, a licenced investment advisory research provider (MAS Licence No. FA100056-1). Any information, commentary, recommendations or statements of opinion provided here are for general information purposes only. It is not intended be personalised investment advice or a solicitation for the purchase or sale of securities. Before purchasing any discussed securities, please be sure actions are in line with your investment objectives, financial situation and particular needs. International investors may be subject to additional risks arising from currency fluctuations and/or local taxes or restrictions. The information contained in this publication are obtained from, or based upon publicly available sources that we believe to reliable, but we make no warranty as to their accuracy or usefulness of the information provided, and accepts no liability for losses incurred by readers using research. Recommendations and opinions are subject to change without notice. Please remember that investments can go up and down, including the possibility a stock could lose all of its value. Past performance is not indicative of future results.

Copyright © 2018 The Motley Fool Singapore Pte. Ltd. All rights reserved. Company Reg. No. 201227853N